Kazia Therapeutics ( (KZIA) ) has released a notification of late filing.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Kazia Therapeutics Limited has announced a delay in filing its Form 20-F (Yearly Report) for the financial period ending June 30, 2025. The delay is primarily due to the need for additional time to finalize consolidated financial statements and complete audit procedures. The company expects to file the report by the fifteenth calendar day following the original due date of October 31, 2025. Kazia Therapeutics does not anticipate any significant changes in its financial results compared to the previous fiscal year. The notification was signed by John Friend, the Chief Executive Officer, as part of the company’s ongoing compliance efforts.
The most recent analyst rating on (KZIA) stock is a Buy with a $13.00 price target. To see the full list of analyst forecasts on Kazia Therapeutics stock, see the KZIA Stock Forecast page.
Spark’s Take on KZIA Stock
According to Spark, TipRanks’ AI Analyst, KZIA is a Underperform.
Kazia Therapeutics has a low overall stock score due to significant financial instability marked by declining revenues, negative equity, and cash flow issues. Technical indicators suggest bearish momentum, and poor valuation metrics reflect the company’s unprofitability. The absence of dividends and positive earnings call or corporate events data further emphasize the company’s challenges.
To see Spark’s full report on KZIA stock, click here.
More about Kazia Therapeutics
Average Trading Volume: 138,629
Technical Sentiment Signal: Sell
Current Market Cap: $12.83M
Learn more about KZIA stock on TipRanks’ Stock Analysis page.